Silexion Therapeutics
Clinical-stage biotechnology company developing RNA interference (siRNA) therapeutics and local extended‑release biodegradable polymer microparticle delivery systems for KRAS-driven solid tumors. Lead candidate is designed for intratumoral administration in locally advanced pancreatic cancer. The company completed Phase 1/2 clinical work with a first‑generation implant and is advancing a second‑generation siRNA‑microparticle product through preclinical studies, toxicology, GMP preparation and regulatory interactions.
Industries
Nr. of Employees
small (1-50)
Silexion Therapeutics
Products
SIL‑204 (siRNA in extended‑release PLG microparticles)
Second‑generation siRNA microparticle candidate composed of chemically modified siRNA sequences targeting oncogenic KRAS mutations formulated within PLG microparticles for prolonged intratumoral release and improved tumor penetration; intended for direct intratumoral administration in KRAS‑mutant locally advanced pancreatic cancer and evaluated in preclinical models for additional KRAS‑driven tumors.
First‑generation prolonged‑release siRNA implant
Earlier biodegradable polymeric implant formulation that released siRNA locally and was evaluated in Phase 1/2 clinical studies; served as a basis for optimization to a microparticle suspension format.
SIL‑204 (siRNA in extended‑release PLG microparticles)
Second‑generation siRNA microparticle candidate composed of chemically modified siRNA sequences targeting oncogenic KRAS mutations formulated within PLG microparticles for prolonged intratumoral release and improved tumor penetration; intended for direct intratumoral administration in KRAS‑mutant locally advanced pancreatic cancer and evaluated in preclinical models for additional KRAS‑driven tumors.
First‑generation prolonged‑release siRNA implant
Earlier biodegradable polymeric implant formulation that released siRNA locally and was evaluated in Phase 1/2 clinical studies; served as a basis for optimization to a microparticle suspension format.
Expertise Areas
- RNAi therapeutics development
- Intratumoral drug delivery and extended‑release polymeric formulations
- Preclinical oncology efficacy and safety testing
- Clinical trial design and clinical operations for oncology
Key Technologies
- Small interfering RNA (siRNA) / RNA interference
- Poly(lactide‑co‑glycolide) (PLG) biodegradable microparticles
- Image‑guided endoscopic intratumoral injection
- Chemical modification of oligonucleotides (to enhance stability and penetration)